SCA
HZNP

Stonebridge Capital Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Stonebridge Capital Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-450
Closed -$52.1K – 921
2023
Q3 		$52.1K Buy
450
+400
+800% +$43K 0.01% 354
2023
Q2 		$5.14K Hold
50
– – ﹤0.01% 714
2023
Q1 		$5.46K Hold
50
– – ﹤0.01% 702
2022
Q4 		$5.69K Sell
50
-400
-89% -$33.2K ﹤0.01% 681
2022
Q3 		$28K Sell
450
-200
-31% -$14K ﹤0.01% 422
2022
Q2 		$52K Hold
650
– – 0.01% 346
2022
Q1 		$68K Buy
650
+550
+550% +$53.6K 0.01% 344
2021
Q4 		$11K Hold
100
– – ﹤0.01% 631
2021
Q3 		$11K Buy
+100
New +$10.4K ﹤0.01% 610

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.05B AUM 19.75% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Stonebridge Capital Advisors's HZNP Position: Q4 2023 in Review

Stonebridge Capital Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 450 shares — an estimated $52.1K sold.

Stonebridge Capital Advisors first reported a position in HZNP in Q3 2021 and held it in 9 quarters. The position peaked at $68K in Q1 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Stonebridge Capital Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Stonebridge Capital Advisors sold 450 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $52.1K.
  • Stonebridge Capital Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 9 quarters.
  • Stonebridge Capital Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $68K in Q1 2022.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Stonebridge Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.